Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results
SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday, July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European Time members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss today's announcement of the interim results of its phase II/III RAPID trial comparing CHOP-R to CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R, in first-line treatment of patients with aggressive non-Hodgkin's lymphoma.
Conference Call Numbers Wednesday, July 11 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European 1-800-240-7305 (US Participants) 1-303-262-2137 (International) Live audio webcast at www.cticseattle.com will be archived for post listening approximately two hours after call ends, available for five days Call-back numbers for post listening available at 6:30 p.m. Eastern: 1-800-405-2236 (US Participants) 1-303-590-3000 (International) Passcode: 11093505# Media Contact: Cell Therapeutics, Inc. Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 E: www.cticseattle.com/media.htm Investors Contact: Cell Therapeutics, Inc. Leah Grant T: 206.282.7100 F: 206.272.4434 E: email@example.com firstname.lastname@example.org
CONTACT: media, Dan Eramian, +1-206-272-4343, or cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, or fax, +1-206-272-4434, or, or investors, Leah Grant, +1-206-282-7100, or fax,+1-206-272-4434, or , all for Cell Therapeutics, Inc. email@example.com firstname.lastname@example.org
Web site: http://www.cticseattle.com//
Ticker Symbol: (NASDAQ-NMS:CTIC)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: July 2007